| Budigalimab |
ABBV-181 |
Phase 3 Clinical |
Abbvie Inc |
HIV Infections; Solid tumours; Head and Neck Neoplasms; Squamous Cell Carcinoma of Head and Neck; Small Cell Lung Carcinoma; Pancreatic Neoplasms; Neoplasms; Triple Negative Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung |
Details
|
| Cetrelimab |
JNJ-63723283; JNJ-3283 |
Phase 3 Clinical |
Johnson & Johnson |
Solid tumours; Hepatitis B, Chronic; Neoplasms; Carcinoma, Transitional Cell; Pancreatic Neoplasms; Urinary Bladder Neoplasms; Multiple Myeloma; Prostatic Neoplasms, Castration-Resistant; Prostatic Neoplasms; Carcinoma, Neuroendocrine; Carcinoma, Small Cell; Melanoma; Carcinoma, Non-Small-Cell Lung |
Details
|
| Nofazinlimab |
CS-1003 |
Phase 3 Clinical |
Cstone Pharmaceuticals |
Solid tumours; Neoplasms; Lymphoma; Carcinoma, Hepatocellular |
Details
|
| Sasanlimab |
RN-888; PF-06801591; PF-6801591 |
Phase 3 Clinical |
Pfizer Inc |
Endometrial Neoplasms; Lymphoma, Large B-Cell, Diffuse; Digestive System Neoplasms; Urinary Bladder Neoplasms; Urologic Diseases; Sarcoma; Prostatic Neoplasms; Bile Duct Neoplasms; Urologic Neoplasms; Colorectal Neoplasms; Triple Negative Breast Neoplasms; Urogenital Neoplasms; Carcinoma, Squamous Cell; Gastrointestinal Neoplasms; Melanoma; Carcinoma, Non-Small-Cell Lung; Fructose Intolerance; Adenocarcinoma; Uterine Cervical Neoplasms; Carcinoma, Renal Cell; Ovarian Neoplasms; Kidney Neoplasms; Liver Neoplasms; Head and Neck Neoplasms; Lymphoma, T-Cell, Peripheral; Skin Melanoma; Esophageal Neoplasms; Stomach Neoplasms; Carcinoma; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Pancreatic Neoplasms; Neoplasms; Neoplasms, Glandular and Epithelial; Kidney Diseases; Carcinoma, Transitional Cell; Carcinoma, Ovarian Epithelial; Hodgkin Disease |
Details
|
| BAT-1308 |
BAT-1308 |
Phase 3 Clinical |
Bio-Thera Solutions Ltd |
Solid tumours; Triple Negative Breast Neoplasms; Endometrial Neoplasms; Uterine Cervical Neoplasms |
Details
|
| Genolimzumab |
CBT-501; APL-501; APL501; GB226; GB-226 |
Phase 3 Clinical |
Cbt, Genor Biopharma Co Ltd, Apollomics Inc |
Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms; Carcinoma, Hepatocellular; Lymphoma, Non-Hodgkin; Sarcoma, Alveolar Soft Part; Thymoma; Lymphoma; Neoplasms, Unknown Primary; Lymphoma, T-Cell, Peripheral; Thymus Neoplasms; Microsatellite Instability; Hodgkin Disease; Carcinoma, Renal Cell; Mismatch Repair Deficient Cancer; Lymphoma, B-Cell; Solid tumours |
Details
|
| Volrustomig |
MEDI-5752; MEDI5752 |
Phase 3 Clinical |
Medimmune Llc |
Biliary Tract Neoplasms; Solid tumours; Esophageal Neoplasms; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Carcinoma, Renal Cell; Mesothelioma; Sarcoma; Bile Duct Neoplasms; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms; Carcinoma, Hepatocellular |
Details
|
| BCD-217 |
BCD-217 |
Phase 3 Clinical |
Biocad |
Melanoma |
Details
|
| Tebotelimab |
PD-1 X LAG-3; MGD-013 |
Phase 3 Clinical |
Macrogenics Inc |
Triple Negative Breast Neoplasms; Adenocarcinoma; Carcinoma, Hepatocellular; Melanoma; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms; Neoplasm Metastasis; Endometrial Neoplasms; Cholangiocarcinoma; Neoplasms; Solid tumours; Small Cell Lung Carcinoma; Esophageal Neoplasms; Stomach Neoplasms; Squamous Cell Carcinoma of Head and Neck; Liver Neoplasms; Biliary Tract Neoplasms; Hematologic Neoplasms; Ovarian Neoplasms; Head and Neck Neoplasms |
Details
|
| Rulonilimab |
F-520 |
Phase 3 Clinical |
Shandong New Time Pharmaceutical Co Ltd |
Lymphoma, T-Cell, Peripheral; Solid tumours; Lymphoma, Large B-Cell, Diffuse; Neoplasms; Carcinoma, Transitional Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular; Central Nervous System Lymphoma; Uterine Cervical Neoplasms |
Details
|
| Pembrolizumab biosimilar (Amgen) |
ABP 234; ABP-234 |
Phase 3 Clinical |
Amgen Inc |
Carcinoma, Non-Small-Cell Lung |
Details
|
| Pembrolizumab biosimilar (Laboratorio Elea Phoenix Sa) |
MB-12; MB12 |
Phase 3 Clinical |
Laboratorio Elea Phoenix Sa |
Carcinoma, Non-Small-Cell Lung |
Details
|
| Pembrolizumab biosimilar(R-Pharm) |
RPH-075 |
Phase 3 Clinical |
R-Pharm |
Skin Melanoma; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Squamous Cell; Carcinoma, Non-Small-Cell Lung |
Details
|
| Pembrolizumab Biosimilar (Samsung Bioepis ) |
SB27; SB-27 |
Phase 3 Clinical |
Samsung Bioepis Co Ltd |
Carcinoma, Non-Small-Cell Lung |
Details
|
| GME-751 |
GME751; GME-751 |
Phase 3 Clinical |
Sandoz |
Melanoma; Carcinoma, Non-Small-Cell Lung |
Details
|
| BAT-3306 |
BAT3306; BAT-3306 |
Phase 3 Clinical |
Bio-Thera Solutions Ltd |
Carcinoma, Non-Small-Cell Lung |
Details
|
| PD-1 Inhibitor Therapy(Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University) |
|
Phase 3 Clinical |
Sun Yat-Sen Memorial Hospital Of Sun Yat-Sen University |
Rejection of liver transplantation; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Hepatocellular |
Details
|
| Nivolumab biosimilar(Amgen) |
ABP-206 |
Phase 3 Clinical |
Amgen Inc |
Melanoma |
Details
|
| Pembrolizumab biosimilar (biocad) |
BCD-201 |
Phase 3 Clinical |
Biocad |
Solid tumours; Melanoma; Carcinoma, Non-Small-Cell Lung |
Details
|
| MK-3475A |
MK-3475A |
Phase 3 Clinical |
Merck Sharp & Dohme Corp |
Solid tumours; Ovarian Neoplasms; Carcinoma, Renal Cell; Lung Neoplasms; Carcinoma, Squamous Cell; Melanoma; Carcinoma, Non-Small-Cell Lung |
Details
|
| Pembrolizumab/Vibostolimab |
MK-7684A |
Phase 3 Clinical |
Merck & Co Inc |
Urinary Bladder Neoplasms; Carcinoma, Hepatocellular; Uterine Cervical Neoplasms; Carcinoma, Non-Small-Cell Lung; Melanoma; Gallbladder Neoplasms; Endometrial Neoplasms; Lung Neoplasms; Cholangiocarcinoma; Ovarian Neoplasms; Triple Negative Breast Neoplasms; Neoplasms; Small Cell Lung Carcinoma; Stomach Neoplasms; Esophageal Neoplasms; Squamous Cell Carcinoma of Head and Neck; Hematologic Neoplasms |
Details
|
| Rilvegostomig |
AZD-2936 |
Phase 3 Clinical |
Astrazeneca Plc |
Biliary Tract Neoplasms; Solid tumours; Stomach Neoplasms; Esophageal Neoplasms; Squamous Cell Carcinoma of Head and Neck; Bile Duct Neoplasms; Carcinoma, Non-Small-Cell Lung |
Details
|
| Pembrolizumab/Quavonlimab |
MK-1308A |
Phase 3 Clinical |
Merck Sharp & Dohme Corp, Msd Ireland (Carlow), MSD R&D（China）Co Ltd |
Solid tumours; Carcinoma, Renal Cell; Small Cell Lung Carcinoma; Colorectal Neoplasms; Carcinoma, Hepatocellular; Melanoma |
Details
|
| Mavezelimab/Pembrolizumab |
MK-4280A; MK-4820A |
Phase 3 Clinical |
Msd Ireland (Carlow) Merck Sharp & Dohme Corp, MSD R&D（China）Co Ltd |
Solid tumours; Carcinoma, Renal Cell; Hodgkin Disease; Carcinoma, Transitional Cell; Small Cell Lung Carcinoma; Colorectal Neoplasms; Carcinoma, Squamous Cell; Endometrial Neoplasms |
Details
|
| Nivolumab biosimilar (Shandong Boan Biotechnology) |
LY-01015; BA-1104 |
Phase 3 Clinical |
Shandong Boan Biotechnology Co Ltd |
Liver Neoplasms; Carcinoma, Renal Cell; Stomach Neoplasms; Squamous Cell Carcinoma of Head and Neck; Esophageal Neoplasms; Urinary Bladder Neoplasms; Mesothelioma; Glioma; Esophageal Squamous Cell Carcinoma; Melanoma; Carcinoma, Non-Small-Cell Lung |
Details
|
| Spartalizumab |
PDR-001 |
Phase 3 Clinical |
Novartis Pharma Ag |
Esophageal Squamous Cell Carcinoma; Chordoma; Digestive System Neoplasms; Neuroendocrine Tumors; Nasopharyngeal Carcinoma; Breast Neoplasms; Sarcoma; Prostatic Neoplasms; Cholangiocarcinoma; Colorectal Neoplasms; Gastrointestinal Stromal Tumors; Primary Myelofibrosis; Bone Marrow Diseases; Esophageal adenocarcinoma; Endometrial Neoplasms; Carcinoma, Squamous Cell; Microsatellite instability-high cancer; Carcinoma, Pancreatic Ductal; Lung Neoplasms; Lymphoma; Sarcoma, Alveolar Soft Part; Leukemia, Myeloid, Acute; Thyroid Neoplasms; Metastatic breast cancer; Uterine Neoplasms; Adenocarcinoma; Persistent Fetal Circulation Syndrome; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Melanoma; Uterine Cervical Neoplasms; Lymphoma, Large B-Cell, Diffuse; Solid tumours; Ovarian Neoplasms; Liver Neoplasms; Leukemia, Myeloid; Leukemia; Kidney Neoplasms; Preleukemia; Hematologic Diseases; Carcinoma, Renal Cell; Carcinoma; Stomach Neoplasms; Squamous Cell Carcinoma of Head and Neck; Anus Neoplasms; Triple Negati |
Details
|
| CD19-PD1-CAR T cell therapy (Chinese PLA General Hospital) |
|
Phase 2 Clinical |
Pla General Hospital |
Lymphoma, B-Cell |
Details
|
| dPD-1 hCD19 CART cell therapy (Innovative Cellular Therapeutics) |
ICTCAR-014 |
Phase 2 Clinical |
Innovative Cellular Therapeutics Co Ltd |
Lymphoma, Non-Hodgkin |
Details
|
| Pimivalimab |
JTX-4014 |
Phase 2 Clinical |
Jounce Therapeutics Inc |
Neoplasms; Carcinoma, Non-Small-Cell Lung |
Details
|
| MAX-10181 |
MAX-10181; MAX-1 |
Phase 2 Clinical |
Maxinovel Pharmaceuticals Co Ltd |
Solid tumours; Neoplasms |
Details
|
| Tobemstomig |
RO-7247669 |
Phase 2 Clinical |
F. Hoffmann-La Roche Ltd |
Solid tumours; Liver Neoplasms; Carcinoma; Carcinoma, Renal Cell; Neoplasms; Carcinoma, Transitional Cell; Breast Neoplasms; Esophageal Squamous Cell Carcinoma; Melanoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular |
Details
|
| SI-B003 |
SI-B003 |
Phase 2 Clinical |
Sichuan Baili Pharmaceutical Co Ltd |
Solid tumours; Stomach Neoplasms; Esophageal Neoplasms; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Renal Cell; Carcinoma, Transitional Cell; Small Cell Lung Carcinoma; Triple Negative Breast Neoplasms; Breast Neoplasms; Nasopharyngeal Carcinoma; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms; Neoplasm Metastasis; Melanoma |
Details
|
| Multiple target antigen stimulating cell therapy (HengRui YuanZheng Biotechnology) |
|
Phase 2 Clinical |
Hengrui Yuanzheng (Shanghai) Biotechnology Co Ltd |
Solid tumours; Liver Neoplasms; Stomach Neoplasms; Neoplasms; Liver Diseases |
Details
|
| Vudalimab |
XmAb-20717; XmAb-717; XmAb 717 |
Phase 2 Clinical |
Xencor Inc |
Thymoma; Adenocarcinoma, Clear Cell; Cholangiocarcinoma; Nasopharyngeal Carcinoma; Breast Neoplasms; Vulvar Neoplasms; Prostatic Neoplasms; Astrocytoma; Colorectal Neoplasms; Endometrial Neoplasms; Microsatellite instability-high cancer; Carcinoma, Neuroendocrine; Carcinoma, Squamous Cell; Fallopian Tube Neoplasms; Thyroid Neoplasms; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms; Melanoma; Carcinoma, Hepatocellular; Carcinoma, Ovarian Epithelial; Ovarian Neoplasms; Solid tumours; Esophageal Neoplasms; Stomach Neoplasms; Carcinoma, Renal Cell; Carcinoma, Basal Cell; Squamous Cell Carcinoma of Head and Neck; Rectal Neoplasms; Biliary Tract Neoplasms; Carcinoma, Transitional Cell; Small Cell Lung Carcinoma; Hodgkin Disease; Adenoma, Acidophil; Colonic Neoplasms; Mesothelioma; Adnexal Diseases; Prostatic Neoplasms, Castration-Resistant |
Details
|
| Recombinant humanized anti-PD-1 monoclonal antibody (Shanghai CP Guojian) |
609-A; SSGJ-609A; SSGJ-609-A |
Phase 2 Clinical |
Sunshine GuoJian Pharmaceutical (Shanghai) Co Ltd |
Solid tumours; Sarcoma; Breast Neoplasms |
Details
|
| Lorigerlimab |
MGD-019; AEX1344 |
Phase 2 Clinical |
Macrogenics Inc |
Solid tumours; Liver Neoplasms; Skin Melanoma; Carcinoma, Renal Cell; Carcinoma, Ovarian Epithelial; Neoplasms; Prostatic Neoplasms, Castration-Resistant; Prostatic Neoplasms; Colorectal Neoplasms; Carcinoma, Squamous Cell; Carcinoma, Pancreatic Ductal; Uterine Cervical Neoplasms; Neoplasm Metastasis; Melanoma; Carcinoma, Non-Small-Cell Lung |
Details
|
| PD-1 knockout EBV-CTL (Nanjing Medical University) |
|
Phase 2 Clinical |
Nanjing Medical University |
Stomach Neoplasms; Hodgkin Disease; Lymphoma, Large B-Cell, Diffuse; Nasopharyngeal Neoplasms; Lymphoma |
Details
|
| Izuralimab |
XmAb-23104; XmAb-104 |
Phase 2 Clinical |
Xencor Inc |
Sarcoma; Uterine Cervical Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Melanoma; Endometrial Neoplasms; Colorectal Neoplasms; Breast Neoplasms; Nasopharyngeal Carcinoma; Solid tumours; Small Cell Lung Carcinoma; Pancreatic Neoplasms; Carcinoma, Transitional Cell; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Renal Cell; Stomach Neoplasms; Esophageal Neoplasms |
Details
|
| Peresolimab |
LY-3462817 |
Phase 2 Clinical |
Eli Lilly And Company |
Arthritis, Rheumatoid; Autoimmune Diseases; Connective Tissue Diseases; Immune System Diseases; Joint Diseases; Psoriasis; Musculoskeletal Diseases; Rheumatic Diseases; Arthritis |
Details
|
| Lomvastomig |
RG-7769; RO-7121661 |
Phase 2 Clinical |
F. Hoffmann-La Roche Ltd |
Solid tumours; Neoplasms; Small Cell Lung Carcinoma; Esophageal Squamous Cell Carcinoma; Carcinoma, Non-Small-Cell Lung; Melanoma |
Details
|
| MiHA-loaded PD-L silenced DC vaccination (Radboud University) |
|
Phase 2 Clinical |
Radboud University Nijmegen |
Hematologic Neoplasms; Colorectal Neoplasms |
Details
|
| ZG-005 |
ZG-005 |
Phase 2 Clinical |
Gensun Biopharma Inc |
Solid tumours; Neoplasms; Carcinoma, Neuroendocrine; Uterine Cervical Neoplasms |
Details
|
| T-3011 |
T-3 (ImmVira Pharma); MVR-T3011; T3011; MVR-T3011 IT; MVR-T3011 IV; B015; B-015 |
Phase 2 Clinical |
Immvira Co Ltd |
Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Melanoma; Carcinoma, Squamous Cell; Lymphoma; Endometrial Neoplasms; Lung Neoplasms; Colorectal Neoplasms; Sarcoma; Liver Neoplasms; Ascites; Mesothelioma; Small Cell Lung Carcinoma; Skin Neoplasms; Squamous Cell Carcinoma of Head and Neck; Esophageal Neoplasms; Head and Neck Neoplasms; Solid tumours; Ovarian Neoplasms |
Details
|
| Anti-CTLA-4 and PD-1 CAR-T cell therapy (Shanghai Cell Therapy Research Institute) |
|
Phase 2 Clinical |
Shanghai Cell Therapy Research Institute |
Neoplasms |
Details
|
| TY-101 |
TY-101; TY101 |
Phase 2 Clinical |
Tayu Huaxia Biotech Medical Group Co Ltd |
Solid tumours; Lymphoma |
Details
|
| BCMA-PD1 CAR T cell therapy (General Hospital of the People's Liberation Army) |
|
Phase 2 Clinical |
People'S Liberation Army General Hospital Military Service |
Multiple Myeloma |
Details
|
| Sabestomig |
AZD-7789 |
Phase 2 Clinical |
AstraZeneca Ag |
Solid tumours; Esophageal Neoplasms; Stomach Neoplasms; Hodgkin Disease; Digestive System Neoplasms; Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis; Gastrointestinal Neoplasms |
Details
|
| TC-510 |
TC-510 |
Phase 2 Clinical |
Tcr2 Therapeutics Inc |
Ovarian Neoplasms; Solid tumours; Pancreatic Neoplasms; Triple Negative Breast Neoplasms; Mesothelioma; Cholangiocarcinoma; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung; Adenocarcinoma |
Details
|
| Anti-PD-1 Antibody(Jiangxi Provincial Cancer Hospital) |
|
Phase 2 Clinical |
Jiangxi Provincial Cancer Hospital |
Nasopharyngeal Carcinoma |
Details
|
| Ezabenlimab |
BI-754091 |
Phase 2 Clinical |
C.H. Boehringer Sohn Ag & Co. Kg |
Sarcoma; Melanoma; Neoplasm Metastasis; Carcinoma, Non-Small-Cell Lung; Gastrointestinal Neoplasms; Lung Neoplasms; Carcinoma, Squamous Cell; Esophageal Squamous Cell Carcinoma; Carcinoma, Neuroendocrine; Carcinoma, Pancreatic Ductal; Colorectal Neoplasms; Head and Neck Neoplasms; Colonic Neoplasms; Small Cell Lung Carcinoma; Triple Negative Breast Neoplasms; Neoplasms; Pancreatic Neoplasms; Rectal Neoplasms; Squamous Cell Carcinoma of Head and Neck; Liver Neoplasms; Biliary Tract Neoplasms; Solid tumours |
Details
|
| PD-1 Inhibitor Therapy(Affiliated Hospital of Nantong University) |
|
Phase 2 Clinical |
Affiliated Hospital Of Nantong University |
Esophageal Squamous Cell Carcinoma |
Details
|
| PD-1 inhibitor therapy(Shanghai Chest Hospital) |
|
Phase 2 Clinical |
Shanghai Chest Hospital |
Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma |
Details
|
| Recombinant humanized anti-PD-1 monoclonal antibody (Anhui Anke Biotechnology) |
|
Phase 2 Clinical |
Anhui Anke Biotechnology (Group) Co Ltd |
Esophageal Neoplasms; Carcinoma, Transitional Cell; Triple Negative Breast Neoplasms; Neoplasms; Lymphoma; Lung Neoplasms |
Details
|
| PD-1 Monoclonal Antibody(Sixth Affiliated Hospital Sun Yat-Sen University) |
|
Phase 2 Clinical |
Sixth Affiliated Hospital Sun Yat-Sen University |
Neoplasms; Colorectal Neoplasms |
Details
|
| PD-1 Inhibitor Therapy(Beijing YouAn Hospital) |
|
Phase 2 Clinical |
Beijing Youan Hospbeijing Youan Hospital,Capital Medical Universityital,Capital Medical University, Beijing Gene Key Life Technology Co Ltd |
Carcinoma, Hepatocellular |
Details
|
| Autologous PD-1 antibody expressing mesothelin-targeted CAR-Tcells therapy (Shanghai Cell Therapy Research Institute) |
|
Phase 2 Clinical |
Shanghai Cell Therapy Research Institute |
Solid tumours |
Details
|
| SAR-445877 |
SAR445877; SAR-445877; KD050; KD-050 |
Phase 2 Clinical |
Sanofi, Kadmon Corporation Llc |
Solid tumours |
Details
|
| Peramprizumab |
|
Phase 2 Clinical |
Sun Yat-Sen University |
Nasopharyngeal Carcinoma |
Details
|
| IBI-363 |
IBI-363 |
Phase 2 Clinical |
Innovent Biologics(Suzhou) Co Ltd |
Solid tumours; Neoplasms; Lymphoma; Melanoma |
Details
|
| EBV-specific TCR-T cell with anti-PD1 auto-secreted element |
|
Phase 2 Clinical |
Tcrcure Biopharma Ltd |
Squamous Cell Carcinoma of Head and Neck |
Details
|
| Anti-CTLA-4/PD-1 expressing EGFR-CAR-T |
|
Phase 2 Clinical |
Shanghai Cell Therapy Research Institute |
Solid tumours |
Details
|
| HerinCAR-PD1 |
|
Phase 2 Clinical |
Ningbo Cancer Hospital |
Solid tumours |
Details
|
| IAP-0971 |
IAP-0971 |
Phase 2 Clinical |
SunHo (China) BioPharmaceutical Co Ltd |
Solid tumours; Neoplasms; Urinary Bladder Neoplasms |
Details
|
| Rosnilimab |
ANB-030 |
Phase 2 Clinical |
Anaptysbio Inc |
Alopecia Areata; Arthritis, Rheumatoid; Colitis, Ulcerative |
Details
|
| TQB-2868 |
TQB-2868 |
Phase 2 Clinical |
Nanjing Shunxin Pharmaceuticals Co Ltd Of Chiatai Tianqing Pharmaceutical Group |
Neoplasms; Pancreatic Neoplasms; Carcinoma, Hepatocellular; Uterine Cervical Neoplasms |
Details
|
| Pidilizumab |
MDV-9300; CT-011 |
Phase 2 Clinical |
Curetech Ltd |
Ovarian Neoplasms; Carcinoma, Renal Cell; Lymphoma, Large B-Cell, Diffuse; Pancreatic Neoplasms; Colonic Neoplasms; Multiple Myeloma; Prostatic Neoplasms; Breast Neoplasms; Sarcoma; Colorectal Neoplasms; Lymphoma; Lymphoma, Non-Hodgkin; Hepatitis C, Chronic; Melanoma; Carcinoma, Hepatocellular |
Details
|
| Pradusinstobart |
LVGN-3616; SSI-361 |
Phase 2 Clinical |
Lyvgen Biopharma(HK)Ltd |
Head and Neck Neoplasms; Solid tumours; Ovarian Neoplasms; Squamous Cell Carcinoma of Head and Neck; Esophageal Neoplasms; Stomach Neoplasms; Neoplasms; Papillomavirus Infections; Uveal melanoma; Sarcoma; Carcinoma, Hepatocellular; Neoplasm Metastasis |
Details
|
| LBL-015 |
LBL-015 |
Phase 2 Clinical |
Nanjing Leads Biolabs Co Ltd |
Solid tumours |
Details
|
| EMB-02 |
EMB-02 |
Phase 2 Clinical |
Shanghai Epimab Biotherapeutics, Inc |
Solid tumours |
Details
|
| Acrixolimab |
YBL-006; YBL 006 |
Phase 2 Clinical |
Y-biologics Inc |
Solid tumours |
Details
|
| PD-1 knockout engineered T cells (Anhui Kedgene Biotechnology) |
|
Phase 2 Clinical |
Anhui Korton Biological Technology Co Ltd, Hangzhou Cancer Hospital |
Esophageal Neoplasms; Carcinoma, Hepatocellular |
Details
|
| Lipustobart |
LZM-009 |
Phase 2 Clinical |
Livzon(Group) Pharmaceutical Factory |
Solid tumours; Thymoma; Carcinoma, Non-Small-Cell Lung |
Details
|
| PD-1 knockout engineered T cells (Chengdu MedGenCell) |
|
Phase 2 Clinical |
West China Hospital Of Sichuan University, Chengdu Medgencell |
Lung Neoplasms; Carcinoma, Non-Small-Cell Lung; Melanoma |
Details
|
| HX-009 |
HX-009 |
Phase 2 Clinical |
Hanx Biopharmaceutical Co Ltd, Wuhan Hanxiong Biotechnology Co Ltd |
Solid tumours; Liver Neoplasms; Stomach Neoplasms; Lymphoma |
Details
|
| MEDI-0680 |
AMP-514; MEDI-0680 |
Phase 2 Clinical |
Medimmune |
Lymphoma, B-Cell; Kidney Neoplasms; Carcinoma, Renal Cell; Neoplasms |
Details
|
| PE0105 |
PE-0105 |
Phase 1 Clinical |
Shanghai Yunyi Health Technology Development Co Ltd |
Solid tumours; Neoplasms |
Details
|
| Recombinant human PD-1 antibody herpes simplex virus |
|
Phase 1 Clinical |
Yangsheng Tang Co Ltd, Xiamen University |
Liver Neoplasms; Solid tumours; Head and Neck Neoplasms; Neoplasms; Pancreatic Neoplasms; Urinary Bladder Neoplasms; Central Nervous System Neoplasms; Colorectal Neoplasms; Brain metastases; Lung Neoplasms; Melanoma; Uterine Cervical Neoplasms |
Details
|
| GX-P1 |
GX-P1 |
Phase 1 Clinical |
Genexine Inc |
Autoimmune Diseases |
Details
|
| Fidasimtamab |
IBI-315 |
Phase 1 Clinical |
Hanmi Pharmaceutical Co Ltd, Innovent Biologics(Suzhou) Co Ltd |
Solid tumours; Neoplasms |
Details
|
| Zeluvalimab |
AMG-404 |
Phase 1 Clinical |
Amgen Inc |
Solid tumours; Small Cell Lung Carcinoma; Prostatic Neoplasms, Castration-Resistant; Precursor Cell Lymphoblastic Leukemia-Lymphoma |
Details
|
| CC-90006 |
C-90006; CC-90006 |
Phase 1 Clinical |
Anaptysbio Inc |
Autoimmune Diseases; Psoriasis |
Details
|
| RO-7284755 |
RO-7284755 |
Phase 1 Clinical |
F. Hoffmann-La Roche Ag |
Solid tumours; Neoplasms |
Details
|
| EGFRvIII-directed CAR-T cell tharapy (Novartis/University of Pennsylvania) |
LXF-821 |
Phase 1 Clinical |
University Of Pennsylvania, Novartis Pharma Ag |
Glioblastoma |
Details
|
| Sym-021 |
Sym-021; S-95016; Sym021 |
Phase 1 Clinical |
Symphogen A/S |
Solid tumours; Lymphoma; Neoplasm Metastasis |
Details
|
| ONO-4685 |
ONO-4685 |
Phase 1 Clinical |
Merus Nv |
Psoriasis; Lymphoma, T-Cell; Plaque psoriasis |
Details
|
| RB-0004 |
RB-0004 |
Phase 1 Clinical |
Reyoung Pharmaceutical Co Ltd |
Solid tumours; Lymphoma |
Details
|
| CMAB-819 |
CMAB8-19 |
Phase 1 Clinical |
Sinomab Bioscience Ltd |
Squamous Cell Carcinoma of Head and Neck; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung |
Details
|
| Taminadenant |
NIR-178; PBF-509 |
Phase 1 Clinical |
Palobiofarma Sl |
Solid tumours; Ovarian Neoplasms; Head and Neck Neoplasms; Carcinoma, Renal Cell; Carcinoma; Triple Negative Breast Neoplasms; Lymphoma, Large B-Cell, Diffuse; Neoplasms; Pancreatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Colorectal Neoplasms; Parkinson Disease; Carcinoma, Pancreatic Ductal; Carcinoma, Non-Small-Cell Lung; Melanoma |
Details
|
| JS-207 |
JS-207 |
Phase 1 Clinical |
Shanghai Junshi Biological Engineering Co Ltd |
Neoplasms |
Details
|
| Mableukin 2PD1 (Anwita Biosciences) |
AWT020; AWT-020 |
Phase 1 Clinical |
Anwita Biosciences Inc |
Neoplasms; Autoimmune Diseases of the Nervous System |
Details
|
| ASKG-915 |
ASKG-915 |
Phase 1 Clinical |
Askgene Pharma |
Solid tumours; Neoplasms |
Details
|
| 707（3SBio） |
|
Phase 1 Clinical |
3sbio Inc |
Solid tumours |
Details
|
| CTX-8371 |
CTX-8371 |
Phase 1 Clinical |
Compass Therapeutics LLC |
Solid tumours; Squamous Cell Carcinoma of Head and Neck; Hodgkin Disease; Triple Negative Breast Neoplasms; Melanoma; Carcinoma, Non-Small-Cell Lung |
Details
|
| Reozalimab |
IBI-318; LY-3434172; LY3434172 |
Phase 1 Clinical |
Innovent Biologics(Suzhou) Co Ltd, Eli Lilly And Company |
Neoplasms; Small Cell Lung Carcinoma; Lymphoma, Extranodal NK-T-Cell; Carcinoma, Squamous Cell; Carcinoma, Hepatocellular |
Details
|
| Toripalimab (Shanghai Junshi Biosciences) |
JS001sc (Shanghai Junshi Biosciences) |
Phase 1 Clinical |
Shanghai Junshi Biosciences Co Ltd |
Neoplasms |
Details
|
| BZT-2312 |
BZT-2312; Fast CAR T cells |
Phase 1 Clinical |
Shanghai Cell Therapy Group Co Ltd |
Solid tumours |
Details
|
| BZE-2209 |
BZE-2209; BZE2209; αPD1/CTLA4-MSLN-CAR T Cells |
Phase 1 Clinical |
Shanghai Cell Therapy Group Co Ltd |
Solid tumours |
Details
|
| BCD-263 |
BCD-263 |
Phase 1 Clinical |
Biocad |
Melanoma |
Details
|
| QL-2107 |
QL2107; QL-2107 |
Phase 1 Clinical |
Qilu Pharmaceutical Co Ltd |
Squamous Cell Carcinoma of Head and Neck; Esophageal Neoplasms; Neoplasms; Triple Negative Breast Neoplasms; Colorectal Neoplasms; Melanoma; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung |
Details
|
| STW204/Gotistobart |
AI-061 |
Phase 1 Clinical |
Oncoc4 Inc |
Colorectal Neoplasms; Gastrointestinal Neoplasms; Carcinoma, Hepatocellular; Melanoma; Uterine Cervical Neoplasms; Carcinoma, Non-Small-Cell Lung; Endometrial Neoplasms; Fallopian Tube Neoplasms; Bile Duct Neoplasms; Carcinoma, Renal Cell; Peritoneal Neoplasms; Digestive System Neoplasms; Urinary Bladder Neoplasms; Stomach Neoplasms; Anus Neoplasms; Esophageal Neoplasms; Squamous Cell Carcinoma of Head and Neck; Cystadenocarcinoma, Serous |
Details
|
| INCA33890 |
INCA33890; INCA-33890 |
Phase 1 Clinical |
Incyte Corp |
Solid tumours; Neoplasms; Neoplasm Metastasis |
Details
|
| INCA-32459 |
INCA-32459 |
Phase 1 Clinical |
Incyte Corp, Merus Nv |
Neoplasms |
Details
|
| JNJ-67484703 |
JNJ-67484703; JNJ-4703 |
Phase 1 Clinical |
Janssen Research & Development Llc |
Arthritis, Rheumatoid |
Details
|
| KY-0118 |
KY-0118; KY0118 |
Phase 1 Clinical |
Novatim Immune Therapeutics (Zhejiang) Co Ltd |
Solid tumours; Carcinoma, Renal Cell; Carcinoma, Transitional Cell; Neoplasms; Pancreatic Neoplasms; Colorectal Neoplasms; Melanoma; Carcinoma, Non-Small-Cell Lung |
Details
|
| Sym-024 |
Sym-024; S-95024 |
Phase 1 Clinical |
Symphogen A/S |
Solid tumours; Neoplasm Metastasis |
Details
|
| SOT-201 |
SOT-201 |
Phase 1 Clinical |
Sotio |
Solid tumours; Neoplasms; Neoplasm Metastasis |
Details
|
| Pegylated recombinant human granulocyte colony stimulating factor(Sun Yat-sen University) |
|
Phase 1 Clinical |
Sun Yat-Sen University |
Hematologic Neoplasms; Nasopharyngeal Carcinoma |
Details
|
| ABBV-1882 |
ABBV-1882 |
Phase 1 Clinical |
Abbvie Inc |
HIV Infections |
Details
|
| CDX-585 |
CDX-585 |
Phase 1 Clinical |
Boaoxin Biotechnology(Nanjing) Co Ltd, Celldex Therapeutics |
Liver Neoplasms; Ovarian Neoplasms; Head and Neck Neoplasms; Solid tumours; Carcinoma, Renal Cell; Esophageal Neoplasms; Stomach Neoplasms; Neoplasms; Pancreatic Neoplasms; Urinary Bladder Neoplasms; Cholangiocarcinoma; Colorectal Neoplasms; Peritoneal Neoplasms; Fallopian Tube Neoplasms; Carcinoma, Non-Small-Cell Lung |
Details
|
| AK-129 |
AK-129 |
Phase 1 Clinical |
Zhongshan Akeso Biopharma Co Ltd |
Neoplasms; Hodgkin Disease |
Details
|
| AK-131 |
AK-131 |
Phase 1 Clinical |
Zhongshan Akeso Biopharma Co Ltd |
Solid tumours; Neoplasms |
Details
|
| 89Zr-N-sucDf-pembrolizumab |
|
Phase 1 Clinical |
Merck & Co Inc, Umcg The University Medical Center Groningen |
Melanoma; Carcinoma, Non-Small-Cell Lung |
Details
|
| 706-3SBio |
SSGJ-706; 706 anti -PD1/PD -L1 BsAb; 706 anti-PD1/PD-L1 Bispecific antibody |
Phase 1 Clinical |
3sbio Inc |
Solid tumours; Composite Lymphoma; Lymphoma |
Details
|
| Latikafusp |
AMG-256 |
Phase 1 Clinical |
Amgen Inc |
Solid tumours |
Details
|
| Recombinant human anti-PD-1 monoclonal antibody(Hec Biological) |
|
Phase 1 Clinical |
Dongguan City Hec Biological Medicine Res And Development Co Ltd |
Stomach Neoplasms; Esophageal adenocarcinoma |
Details
|
| RG-6279 |
RG-6279 |
Phase 1 Clinical |
F. Hoffmann-La Roche Ltd |
Solid tumours |
Details
|
| CA-170 |
CA-170; AUPM-170 |
Phase 1 Clinical |
Aurigene |
Solid tumours |
Details
|
| SHR-1901 |
SHR-1901 |
Phase 1 Clinical |
Suzhou Suncadia Biopharmaceuticals Co Ltd |
Neoplasms |
Details
|
| SSGJ-705 |
705; SSGJ-705 |
Phase 1 Clinical |
Sunshine GuoJian Pharmaceutical (Shanghai) Co Ltd |
Solid tumours; Neoplasms |
Details
|
| Anti-PD1/anti-TIM3 bispecific antibody (L&L vision biopharmaceuticals) |
Bis-5 |
Phase 1 Clinical |
L&L Biopharma Co Ltd |
Solid tumours; Neoplasms |
Details
|
| CD19 PD-1/CD28 CAR-T Cell Therapy (Second Affiliated Hospital School Of Zhejiang University School Of Medicine) |
|
Phase 1 Clinical |
Second Affiliated Hospital Of Zhejiang University School Of Medicine |
Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Lymphoma, Follicular; Primary mediastinal B cell lymphoma |
Details
|
| IBI-321 |
IBI-321 |
Phase 1 Clinical |
Innovent Biologics(Suzhou) Co Ltd |
Solid tumours; Neoplasms |
Details
|
| PH-762 |
PH-762; PH762-ACT; RXI 762-ACT |
Phase 1 Clinical |
Phio Pharmaceuticals Corp |
Skin Melanoma; Squamous Cell Carcinoma of Head and Neck; Skin Neoplasms; Small Cell Lung Carcinoma; Breast Neoplasms; Genital Neoplasms, Female; Colorectal Neoplasms; Carcinoma, Squamous Cell; Urogenital Neoplasms; Lung Neoplasms; Melanoma |
Details
|
| JS-201 |
JS-201 |
Phase 1 Clinical |
Shanghai Junshi Biosciences Co Ltd |
Neoplasms |
Details
|
| IMU-201 |
IMU-201 |
Phase 1 Clinical |
Imugene Ltd |
Adenocarcinoma of Lung; Carcinoma, Large Cell; Carcinoma, Squamous Cell; Lung Neoplasms; Carcinoma, Non-Small-Cell Lung |
Details
|
| CD-200-AR-L |
CD-200-AR-L; hP-1-A-8 |
Phase 1 Clinical |
University Of Minnesota, OX2 Therapeutics |
Glioblastoma; Glioma |
Details
|
| PF-07209960 |
PF-07209960 |
Phase 1 Clinical |
Pfizer Inc |
Squamous Cell Carcinoma of Head and Neck; Carcinoma, Renal Cell; Carcinoma, Transitional Cell; Carcinoma, Ovarian Epithelial; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung |
Details
|
| GNR-051 |
GNR-051 |
Phase 1 Clinical |
Generium Pharmaceuticals |
Carcinoma, Renal Cell; Melanoma; Carcinoma, Non-Small-Cell Lung |
Details
|
| IBI-319 |
IBI-319 |
Phase 1 Clinical |
Innovent Biologics(Suzhou) Co Ltd |
Neoplasms |
Details
|
| NWY-001(Biocytogen Pharmaceuticals) |
NWY001(Biocytogen Pharmaceuticals); YH008; YH-008; NWY-001(Biocytogen Pharmaceuticals) |
Phase 1 Clinical |
Eucure Pharmaceutical Technology (Beijing) Co Ltd, Biocytogen Pharmaceuticals (Beijing) Co Ltd |
Solid tumours; Hematologic Neoplasms; Neoplasms |
Details
|
| VT1093 |
VT1093; VT-1093 |
Phase 1 Clinical |
Beijing Weiyuan Likang Biotechnology Co Ltd |
Solid tumours |
Details
|
| αPD1-MSLN-CAR T cell therapy (Shanghai Cell Therapy Group Co.,Ltd) |
BZDS1901; BZDS-1901; BZD1901 |
Phase 1 Clinical |
Shanghai Cell Therapy Group Co Ltd |
Ovarian Neoplasms; Solid tumours; Mesothelioma; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung |
Details
|
| Recombinant humanized anti-PD-1 monoclonal antibody (Shanxi Wichida Bright Pharmaceutical) |
|
Phase 1 Clinical |
Shanxi Weiqidaguangming Pharmaceutical Co Ltd |
Solid tumours |
Details
|
| MW-11 |
MW-11; 9MW1111; 9-MW1111; 9MW-1111; 9-MW-1111 |
Phase 1 Clinical |
Mabwell (Shanghai) Bioscience Co Ltd |
Solid tumours; Breast Neoplasms |
Details
|
| STW204 |
STW-204; AI025; AI-025 |
Phase 1 Clinical |
Suzhou Stainwei Biotech Inc |
Solid tumours; Neoplasms |
Details
|
| Rituximab/Paclitaxel |
AR-160 |
Phase 1 Clinical |
Mayo Clinic |
Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell |
Details
|
| 64Cu-DOTA-nivolumab (Bristol-Myers Squibb/Ono Pharmaceutical) |
|
Clinical |
Ono Pharmaceutical Co Ltd, Bristol-Myers Squibb Company |
Melanoma; Carcinoma, Non-Small-Cell Lung |
Details
|
| INSIX RA (Indus Biotech) |
|
Clinical |
Indus Biotech Pvt Ltd |
Arthritis, Rheumatoid; Inflammation |
Details
|
| Treprilimab |
|
Clinical |
Sun Yat-Sen University |
Oropharyngeal Neoplasms |
Details
|
| Anti-PD-1 Antibody(Fujian Cancer Hospital) |
|
|
Fujian Cancer Hospital |
|
Details
|
| PD-1 Inhibitor Therapy(Hunan Cancer Hospital) |
|
|
Hunan Cancer Hospital |
|
Details
|
Limited Edition Golden Llama is here! Check out how you can get one. 
Limited Edition Golden Llama is here! Check out how you can get one. 
A-Z
